NCT06367010View on ClinicalTrials.gov

Clinical Efficacy of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients

CompletedOBSERVATIONAL
Enrollment

8

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

April 1, 2024

Study Completion Date

April 1, 2024

Conditions
Thyroid Neoplasms
Interventions
COMBINATION_PRODUCT

Iodine-125 brachytherapy combine with Anlotinib

Iodine-125 brachytherapy combine with Anlotinib

Trial Locations (1)

330029

Jiangxi Cancer Hospital, Nanchang

All Listed Sponsors
lead

Jiangxi Provincial Cancer Hospital

OTHER

NCT06367010 - Clinical Efficacy of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients | Biotech Hunter | Biotech Hunter